Τίτλος:
Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The protein tyrosine phosphatase SHP-1 dephosphorylates BCR-ABL1, thereby serving as a potential control mechanism of BCR-ABL1 kinase activity. Pathways regulating SHP-1 expression, which could be exploited in the therapeutics of TKI-resistant chronic myeloid leukemia (CML), remain unknown. Moreover, the questions of whether there is any kind of SHP-1 deregulation in CML, contributing to disease initiation or evolution, as well as the question of prognostic significance of SHP-1, have not been definitively answered. This study shows moderately lower SHP-1 mRNA expression in chronic phase CML patients in comparison to healthy individuals and no change in SHP-1 mRNA levels after successful TKI treatment. Mutational analysis of the aminoterminal and phosphatase domains of SHP-1 in patients did not reveal genetic lesions. This study also found no correlation of SHP-1 expression at diagnosis with response to treatment, although a trend for lower SHP-1 expression was noted in the very small non-responders group of the 3-month therapeutic milestone. © 2015 Taylor and Francis.
Συγγραφείς:
Papadopoulou, V.
Kontandreopoulou, E.
Panayiotidis, P.
Roumelioti, M.
Angelopoulou, M.
Kyriazopoulou, L.
Diamantopoulos, P.T.
Vaiopoulos, G.
Variami, E.
Kotsianidis, I.
Athina Viniou, N.
Περιοδικό:
Clinical Lymphoma Myeloma and Leukemia
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
BCR ABL protein; protein tyrosine phosphatase SHP 1; BCR ABL protein; protein kinase inhibitor; protein tyrosine phosphatase SHP 1, adult; aged; amino acid sequence; Article; autoregulation; cancer prognosis; chronic myeloid leukemia; clinical article; comparative study; controlled study; exon; female; gene expression; gene frequency; human; male; mutational analysis; pathogenesis; priority journal; protein binding; protein expression; real time polymerase chain reaction; reverse transcription; case control study; dna mutational analysis; gene expression regulation; genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; middle aged; mortality; mutation; myeloid leukemia; prognosis; single nucleotide polymorphism; treatment outcome; very elderly; young adult, Adult; Aged; Aged, 80 and over; Case-Control Studies; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Treatment Outcome; Young Adult
DOI:
10.3109/10428194.2015.1090573
